Aimee Rogers, MD
Urology · Pendleton, ORNPI 1093912693
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (58.5%), food and beverage and education — rather than concentrated in one kind of arrangement. 19 manufacturers reported payments, led by Teleflex LLC at 40.6% of the total. Reporting peaked in 2023 at $2,214 and has fallen 58.2% since, to $925 in 2025.
Across 66 payments — averaging $65.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teleflex LLC$2K
- Axonics, Inc.$974
- Boston Scientific$583
- Myriad Genetic Laboratories, Inc.$174
- AbbVie$158
- Dornier Medtech America, Inc$150
- plus $545 from 13 others
What the payments were for
- Travel & lodging$2,54658%
- Food & beverage$1,68739%
- Education$1213%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teleflex LLC | 13 | $1,768 |
| Axonics, Inc. | 5 | $974 |
| Boston Scientific | 9 | $583 |
| Myriad Genetic Laboratories, Inc. | 9 | $174 |
| AbbVie(2 entities) | 8 | $158 |
| Dornier Medtech America, Inc | 1 | $150 |
| Astellas Pharma US Inc | 4 | $146 |
| Olympus America Inc. | 2 | $121 |
| Sumitomo Pharma America, Inc. | 3 | $74 |
| Progenics Pharmaceuticals, Inc. | 2 | $36 |
| Procept Biorobotics Corporation | 1 | $33 |
| Convatec Inc. | 2 | $30 |
| Cook Medical LLC | 1 | $19 |
| 180 Medical, Inc. | 1 | $19 |
| KARL Storz Endoscopy-america | 1 | $16 |
| Innovation Technologies Inc | 1 | $16 |
| Urovant Sciences Inc | 1 | $15 |
| Ambu Inc. | 1 | $15 |
| Travere Therapeutics, Inc. | 1 | $4 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UroLift$1,435
- Axonics$1,173
- Barrigel$170
- Dornier MedTech$150
How this compares
$4,353 in reported general payments places this provider in the 75th percentile of 153 urology providers in Oregon.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 93 | $49,651 |
| GemtesaVibegron | 21 | $18,779 |
| Tamsulosin Hcl | 470 | $8,776 |
| Oxybutynin Chloride ErOxybutynin Chloride | 287 | $5,914 |
| Mirabegron ErMirabegron | 11 | $5,698 |
| Trospium Chloride ErTrospium Chloride | 27 | $4,335 |
| Tolterodine Tartrate ErTolterodine Tartrate | 31 | $3,043 |
| Finasteride | 133 | $2,519 |
| Estradiol | 35 | $1,967 |
| NitrofurantoinNitrofurantoin Macrocrystal | 79 | $1,776 |
| Fesoterodine Fumarate ErFesoterodine Fumarate | 13 | $1,710 |
| Trospium Chloride | 40 | $1,262 |
| Bicalutamide | 22 | $1,046 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 72 | $957 |
| Cephalexin | 74 | $657 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $146 | $49,65193 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $74 | $18,77921 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 153 urology providers in Oregon.
Other urology in Pendleton
- Bryan MehlhaffSpringfield$1M
- Lance MarrPortland$323K
- Matt AshleyBend$212K
- da David JiangPortland$65K
- Kim ThaiMedford$57K
- Kevin KrughoffSpringfield$54K
- Kyle GillisClackamas$51K
- Amir PatelPortland$36K
- James TycastPortland$35K
- Sudhir IsharwalPortland$30K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.